Author Archives: Charles Moore

Cure Alzheimer’s Awards Over $700,000 to Support 5 Research Efforts

Cure Alzheimer’s Fund, a Massachusetts-based nonprofit dedicated to funding promising research into ways to prevent, slow, or reverse Alzheimer’s disease, has awarded more than $700,000 in research grants in September to scientists working toward those goals. The five newly funded projects brings Cure Alzheimer’s research support for 2016 to more…

$1.7M Grant Given to Move Therapy Targeting Cannabinoid Receptor into Clinical Trials in Alzheimer’s Patients

NeuroTherapia, a Cleveland Clinic spin-off biotech company, has received a $1.7 million funding commitment from the Alzheimer’s Drug Discovery Foundation to advance its lead drug candidate NTRX-07 — a selective cannabinoid type 2 (CB2) receptor agonist that can be orally administered — toward human clinical trials. This therapy targets…

Quest Diagnostics Launches Digital Tool, CogniSense, to Assess Dementia

Quest Diagnostics has announced the release of CogniSense, its digital cognitive assessment tool to assist physicians in diagnosing, assessing, and managing the care of people with cognitive dysfunction. Quest says its design objective for CogniSense was to overcome the various limitations inherent in conventional, paper-based cognitive assessment, such as…

Cannabinoids, Like Those in Marijuana, May Protect Alzheimer’s Patients from Plaque Buildup

Alzheimer’s disease has been described in medical literature for more than a century, but still has no effective treatments. Now, scientists at the Salk Institute in La Jolla, California, report finding evidence that tetrahydrocannabinol (THC), one of several physiologically active chemical compounds in marijuana, can promote cellular removal of amyloid beta, a toxic…